References
- WHO. Immunization coverage. [accessed 2022 Aug 4]. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage.
- Skibinski DA, Baudner BC, Singh M, O’Hagan DT. Combination vaccines. J Glob Infect Dis. 2011;3(1):1–5. doi:10.4103/0974-777X.77298.
- Grassly NC. The final stages of the global eradication of poliomyelitis. Philos Trans R Soc B: Biol Sci. 2013;368(1623):20120140. doi:10.1098/rstb.2012.0140.
- Mahmood K, Pelkowski S, Atherly D, Sitrin R, Donnelly JJ. Hexavalent IPV-based combination vaccines for public sector markets of low-resource countries. Hum Vaccin Immunother. 2013;9(9):1894–902. doi:10.4161/hv.25407.
- Kaufmann SHE. Highly affordable vaccines are critical for our continued efforts to reduce global childhood mortality. Hum Vaccin Immunother. 2019;15(11):2660–65. doi:10.1080/21645515.2019.1605817.
- World Health Organization & Global Polio Eradication Initiative. Polio eradication strategy 2022–2026: delivering on a promise; 2021 [Accessed 2022 Aug 5]. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage.
- Wyman O. The supply landscape and economics of IPV-containing combination vaccines: key findings: commissioned by the Bill & Melinda Gates foundation. 2010. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage.
- Sharma H, Yadav S, Lalwani S, Kapre S, Jadhav S, Parekh S, Palkar S, Ravetkar S, Bahl S, Kumar R, et al. Antibody persistence of two pentavalent DTwP–hb–hib vaccines to the age of 15–18 months, and response to the booster dose of quadrivalent DTwP–hib vaccine. Vaccine. 2013;31(3):444–47. doi:10.1016/j.vaccine.2012.11.038.
- Quiambao B, Van Der Meeren O, Kolhe D, Gatchalian S. A randomized, dose-ranging assessment of the immunogenicity and safety of a booster dose of a combined diphtheria-tetanus-whole cell pertussis-hepatitis B-inactivated poliovirus-Hemophilus influenzae type b (DTPw-HBV-IPV/Hib) vaccine vs. co-administration of DTPw-HBV/Hib and IPV vaccines in 12 to 24 months old Filipino toddlers. Hum Vaccines Immunother. 2012;8:347–54.
- WHO. Information sheet observed rate of vaccine reactions diphtheria, pertussis, tetanus vaccines. World Health Organization. 2014 May [accessed 2022 Aug 5]. https://www.who.int/news-room/fact-sheets/detail/immunization-coverage
- Mangarule S, Palkar S, Mitra M, Ravi MD, Dubey AP, Moureau A, Jayanth MV, Patel DM, Ravinuthala S, Jagga SR, et al. Safety and immunogenicity of a hexavalent DTwP-IPV-HB-PRP∼T vaccine versus separate DTwP-HB-PRP∼T and IPV vaccines in healthy infants in India. Vaccine X. 2022;10:100137. doi:10.1016/j.jvacx.2021.100137.
- Sharma HJ, Yadav S, Lalwani SK, Kapre SV, Jadhav SS, Chakravarty A, Parekh SS, Palkar S, Bhardwaj SH, Namjoshi GS, et al. Immunogenicity and safety of an indigenously manufactured reconstituted pentavalent (DTwP-HBV+Hib) vaccine in comparison with a foreign competitor following primary and booster immunization in Indian children. Hum Vaccin. 2011;7(4):451–57. doi:10.4161/hv.7.4.14208.
- Gandhi DJ, Dhaded SM, Ravi MD, Dubey AP, Kundu R, Lalwani SK, Chhatwal J, Mathew LG, Gupta M, Sharma SD, et al. Safety, immune lot-to-lot consistency and non-inferiority of a fully liquid pentavalent DTwp-HepB-Hib vaccine in healthy Indian toddlers and infants. Hum Vaccin Immunother. 2016;12(4):946–54. doi:10.1080/21645515.2015.1100779.
- Marin M, Patel M, Oberste S, Pallansch MA Guidance for assessment of poliovirus vaccination status and vaccination of children who have received poliovirus vaccine outside the United States. MMWR Morb Mortal Wkly Rep. 2017;66(1):23–25.